CART-cell therapy in autoimmune diseases: where are we and where are we going?

Marc Scherlinger; Gaetane Nocturne; Marko Radic; David Launay; Christophe Richez; Philippe Bousso; Edouard Forcade; Alain Meyer; Christian Jorgensen; Camille Bigenwald; Divi Cornec; Jean Sibilia; Sylvain Choquet; Thierry Martin; Alexandre Belot; Maurine Jouret; Samuel Bitoun; Zahir Amoura; Olivier Hermine; Xavier Mariette; Emmanuel Donnadieu; Jerome Avouac; Club Innovative Immunotherapies Immune-Mediated Inflammatory Dis C3I

doi:10.1016/S2665-9913(24)00377-1

Retour

CART-cell therapy in autoimmune diseases: where are we and where are we going?

Article de revue

Avec comité de lecture

CART-cell therapy in autoimmune diseases: where are we and where are we going?

Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, …

The Lancet. Rheumatology, Vol.7(6), pp.e434-e447

01/06/2025

DOI: https://doi.org/10.1016/S2665-9913(24)00377-1

PMID: 40157379

Résumé

Life Sciences & Biomedicine

Rheumatology

Science & Technology

Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: CART-cell therapy in autoimmune diseases: where are we and where are we going?
Créateurs - sans rôle: Marc Scherlinger - Strasbourg Univ Hosp, Ctr Reference Malad Autoimmunes Syst Est Sud Oues, Rheumatol Dept, Strasbourg, France
Gaetane Nocturne - Univ Paris Saclay, Hop Bicetre, Assistance Publ Hop Paris, Dept Rheumatol, Saclay, Paris, France
Marko Radic - Univ Tennessee, Coll Med, Dept Microbiol Immunol & Biochem, Hlth Sci Ctr, Memphis, TN USA
David Launay - Université de Lille
Christophe Richez - Ctr Natl Reference Malad Autoimmunes Syst Rares R, Serv Rhumatol, Bordeaux, France
Philippe Bousso - Univ Paris Cite, INSERM, Inst Pasteur, Dynam Immune Responses Unit,U1223, Paris, France
Edouard Forcade - Immunology from Concept and Experiments to Translation
Alain Meyer - Strasbourg Univ Hosp, Ctr Reference Malad Autoimmunes Syst Est Sud Oues, Rheumatol Dept, Strasbourg, France
Christian Jorgensen - Ctr Hosp Univ Montpellier, Dept Rheumatol, Clin Immunol & Osteoarticular Dis Therapeut Unit, Montpellier, France
Camille Bigenwald - Univ Paris Saclay, Dept Hematol, Gustave Roussy, Villejuif, France
Divi Cornec - INSERM, Ctr Hosp Univ Brest, Rheumatol Dept, UMR 1227,LBAI, Brest, France
Jean Sibilia - Strasbourg Univ Hosp, Ctr Reference Malad Autoimmunes Syst Est Sud Oues, Rheumatol Dept, Strasbourg, France
Sylvain Choquet - Sorbonne Univ, Hematol Dept, Paris, France
Thierry Martin - Strasbourg Univ Hosp, Ctr Reference Malad Autoimmunes Syst Est Sud Oues, Clin Immunol Dept, Serv Rhumatol, Strasbourg, France
Alexandre Belot - Mother & Children Univ Hosp, Natl Referee Ctr Pediat Onset Rheumatism & Autoim, Pediat Nephrol Rheumatol Dermatol Unit, Hosp Civils Lyon, Lyon, France
Maurine Jouret - Mother & Children Univ Hosp, Natl Referee Ctr Pediat Onset Rheumatism & Autoim, Pediat Nephrol Rheumatol Dermatol Unit, Hosp Civils Lyon, Lyon, France
Samuel Bitoun - Univ Paris Saclay, Hop Bicetre, Assistance Publ Hop Paris, Dept Rheumatol, Saclay, Paris, France
Zahir Amoura - Sorbonne Univ, GHU APHP, Ctr Natl Reference Lupus & Syndrome Anticorps Ant, Serv Med Interne 2,Inst E3M,Ctr Imunol & Malad In, Paris, France
Olivier Hermine - Institut des Maladies Génétiques Imagine
Xavier Mariette - Univ Paris Saclay, Hop Bicetre, Assistance Publ Hop Paris, Dept Rheumatol, Saclay, Paris, France
Emmanuel Donnadieu - Univ Paris Cite, CNRS, INSERM, Equipe Labellisee Ligue Canc,Inst Cochin, Paris, France
Jerome Avouac - Univ Paris Cite, Hop Cochin, Assistance Publ Hop Ctr, Serv Rhumatol, Paris, France
Club Innovative Immunotherapies Immune-Mediated Inflammatory Dis C3I
Détails de publication: The Lancet. Rheumatology, Vol.7(6), pp.e434-e447
Éditeur: Elsevier
Nombre de pages: 14
Note de subvention: Pfizer Galapagos; Galapagos NV Nordic Pharma Roche-Chugai; Roche Holding Roche Chugai; Roche Holding Therakos and Servier Novartis Lilly; Eli Lilly Fresenius Kabi AbbVie
Identifiants: 99141113909311
Unité académique: Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Langue: English
Type de ressource: Journal article